QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: From Safety Concern to Formal EU Referral

Test your understanding of the concepts covered by How an EMA Safety Referral Starts: From Safety Concern to Formal EU Procedure.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why are separate procedural timetables for ordinary pharmacovigilance referrals and Article 107i procedures operationally significant?

They indicate that Article 107i does not require evidence. They reflect different procedural expectations, with urgent procedures potentially requiring parallel and rapid mobilisation of multiple functions. They determine whether the safety concern is causal. They allow the MAH to select whichever timetable is more convenient.

Question 2 of 10 Which statement correctly separates observation, interpretation and regulatory conclusion?

An increase in reporting frequency proves an increase in incidence and requires a label change. Biological plausibility establishes clinical causality. Observed data should be distinguished from scientific interpretation and from the regulatory action justified after considering evidence and uncertainty. A regulatory conclusion is independent of the evidence if the event is serious.

Question 3 of 10 Which statement best describes the MAH's role in a referral?

The MAH negotiates the outcome with EMA and may omit evidence that weakens its position. The MAH provides complete, accurate and reasoned evidence, addresses the formal questions and explains uncertainty and regulatory implications. The MAH is limited to defending the existing product information. The MAH determines which products and questions PRAC will assess.

Question 4 of 10 A referral page is published announcing that a safety issue will be assessed. What may reasonably be concluded at that point?

The risk has been confirmed and withdrawal is imminent. The referral has entered formal assessment, but causality and the final regulatory action remain open. The MAH has accepted the final regulatory position. All products containing the active substance are automatically included.

Question 5 of 10 A later regulatory conclusion differs from an earlier company assessment because substantial new evidence became available. What does this demonstrate by itself?

That the earlier assessment was necessarily a system failure. That the company concealed information. Nothing by itself about system failure; the adequacy of the earlier process must be judged against the information and reasoning available at that time. That the later conclusion must be incorrect.

Question 6 of 10 Which statement correctly describes the relationship between seriousness and urgency?

Any serious safety concern automatically requires Article 107i. Urgency and seriousness are identical regulatory concepts. A concern may be scientifically serious without meeting the statutory criteria for Article 107i, while urgency is determined by the applicable legal circumstances. An urgent procedure does not require scientific assessment.

Question 7 of 10 Why must an MAH map the EU authorisation landscape for an active substance when considering escalation?

Because only products owned by the MAH can ever be assessed. Because the authorisation routes and products potentially affected influence the available Union legal pathways and formal scope. Because the authorisation route determines whether an adverse event is medically serious. Because centrally authorised products are not subject to pharmacovigilance.

Question 8 of 10 A company has products containing the same active substance under several authorisation routes. What is the correct approach after a referral is initiated?

Assume every product containing the active substance is in scope. Assume only the company's centrally authorised product is in scope. Read the formal notification and product list and map those documents against the company's authorisations. Include only products for which the same adverse event has already been reported.

Question 9 of 10 Which statement about initiation authority is accurate?

The MAH can universally choose and initiate any referral legal basis. Only EMA can initiate every type of referral. The initiating authority depends on the legal basis; for example, Article 20 can only be formally initiated by the European Commission. PRAC independently initiates all Article 31 procedures.

Question 10 of 10 Which approach is most appropriate when an MAH begins preparing a response to a formal referral?

Collect every historical document first and determine the regulatory question later. Start with the exact referred questions and map the relevant evidence, uncertainties and potential conclusions to each question. Prepare only arguments supporting retention of the current label. Rely primarily on the number of adverse-event reports.

QPPV.com

Knowledge Assessment: From Safety Concern to Formal EU Referral

Cookie Settings